Longevity: How the Wealthy Spend on Healthspan
The Million Dollar Question: Roughly how much does Bryan Johnson — the tech entrepreneur behind “Project Blueprint” — say he spends each year on his longevity protocol?
A) $200,000 B) $750,000 C) $2 million D) $10 millionRead on for the answer.
There is a 1,000-fold gap between what a careful, motivated adult can spend on longevity in a year — and what Bryan Johnson spends. Almost none of the gap buys additional life expectancy. The piece below walks through the four spending tiers, what each one actually buys, and what most of the wealthy get wrong about what their money is doing.
What it is
Longevity spending, the way the term is used inside the founder-and-physician ecosystem in 2026, is not anti-aging skincare, not concierge medicine in the everyday sense, and not standard health care. It is the deliberate purchase of four things at once: earlier detection of disease, off-label drugs aimed at the biology of aging, experimental interventions whose evidence base is still in motion, and — at the very top — funding of fundamental research that may not produce a useful answer until the funder’s grandchildren are middle-aged.
The category divides cleanly into healthspan and lifespan. Healthspan is the number of years lived in good physical and cognitive function. Lifespan is the number of years lived, period. The wealthy in 2026 are mostly spending on the first and hoping the second follows. The honest version of the field’s pitch is: we cannot promise you more years, but we can probably help you spend the years you have in better shape, and we will know more in a decade.
The financed category is about fifteen years old. Aubrey de Grey’s SENS Foundation pushed the science into philanthropic dollars in the mid-2000s; Google parent Alphabet launched Calico Life Sciences in 2013 with what eventually became roughly $3 billion in combined Alphabet and AbbVie commitments before AbbVie wound down the collaboration in 2024; J. Craig Venter co-founded Human Longevity Inc. the same year; Jeff Bezos and Yuri Milner put $3 billion into Altos Labs at launch in 2022; Bryan Johnson made his $2-million-a-year regimen the subject of a Netflix documentary in 2025. The institutional money since 2013 now exceeds ten billion dollars.
This piece is the spending lens. The speculative-extreme lens — cryonics, radical life extension, billionaire moonshots — sits in the companion piece on moonshots. The everyday-care lens — Sollis, MDVIP, Private Medical — sits in Concierge Medicine. The categories overlap in marketing but the products are different.
Who uses it
Longevity spending splits into four tiers, and they look almost nothing like each other.
The bottom tier is the $1,500–$5,000-a-year DIY stack. Anyone with a real income can afford it, and millions of people do. The buyer is typically a high-earning tech, finance, founder, or physician reader who has read Peter Attia’s Outlive, listens to Andrew Huberman, takes a smart ring or continuous glucose monitor seriously, and runs a supplement stack. The cost is mostly the supplements, one or two epigenetic-age tests a year, and time.
The middle tier is the $5,000–$25,000 diagnostics-and-concierge stack, and it is where the $5M–$30M household typically lives. Members hold a Sollis Health card for ER-bypass urgent care, an MDVIP or similar concierge primary-care relationship for the leisurely annual physical, and once a year a longer diagnostic day at Fountain Life CORE, Human Longevity Executive, or a similar clinic. Total time burden is modest; the protocol is mostly outsourced.
The upper tier is the $25,000–$150,000 full clinic stack, and it is where the $30M–$100M household typically operates. The anchor membership is the high tier at one of the marquee clinics — Fountain Life APEX at $19,500–$21,500, Human Longevity’s 100+ Concierge at $19,000, or a referred relationship with Peter Attia’s clinical practice. Around that anchor are a dietitian on retainer, a longevity-trained personal trainer, quarterly imaging, a personalized supplement and off-label pharmacy regimen, and the time to do all of it.
The top tier is the personal research budget — $250,000 to $2 million or more a year — and it is single-digit households globally as a personal-spend category. Bryan Johnson is the public face. The defining feature is not the supplement stack; it is the full-time staff. A medical director, two or three clinicians, a quantified-self engineer, frequent imaging cycles, custom-compounded interventions, and a willingness to be the first patient through several experimental doors.
Then, in a category of its own, sits the institutional research spend — Bezos and Milner via Altos, Page and Brin via Calico, Larry Ellison via the Ellison Medical Foundation, the Saudi royal family via Hevolution, Yuri Milner via the Breakthrough Prize. This is not a personal regimen; it is venture and philanthropic capital, on ten-to-twenty-year horizons, often by people who are unlikely to be alive when their dollars produce a clinical answer.
Each tier reads about its own tier. Cross-tier marketing — sending a DIY-tier reader a Fountain Life APEX brochure, or pitching Bryan Johnson on an MDVIP membership — produces nothing.
Why they use it
Five drivers, in roughly honest order.
First, the time math. At $30 million or more of net worth, a thoughtful buyer can describe almost any purchase by the years of late-life function it might add. An extra five healthy years between ages 75 and 95 is, on most reasonable utility curves, the most valuable purchase money can attempt. Diagnostic dollars do not always deliver those years, but the framing is unambiguously rational for the buyer.
Second, control orientation. The wealthy population most attracted to longevity spending is disproportionately drawn from high-agency professions — founders, traders, surgeons, partners. The passivity of standard medicine, where a fifteen-minute appointment produces a recommendation to come back in a year, is unbearable to that disposition. Longer visits, more data, and the option to direct the protocol are the product.
Third, information asymmetry. By the time a founder in this category sits down with a longevity clinician, the founder has read Outlive, watched the Don’t Die documentary, subscribed to Peter Attia’s podcast, and has views on rapamycin dosing. The clinic that meets them at that level keeps them; the clinic that does not, loses them in a quarter.
Fourth, status. In the founder ecosystem, knowing the difference between GrimAge and DunedinPACE is status capital the way knowing the difference between a Macallan 18 and a Yamazaki 18 was a generation earlier. Bryan Johnson’s protocol, Andrew Huberman’s morning routine, Tim Ferriss’s blood-panel reports — these are status reading, and the spending follows the status.
Fifth, optionality. If a real breakthrough lands in the next decade — a partial-reprogramming therapy out of Altos, a senolytic with strong human data — the buyers who already have decade-long biomarker baselines and active relationships with longevity clinics will be first in line. Even if the breakthrough never comes, the buyers in the meantime are spending on diagnostics that occasionally find something useful.
Honest counterpoint: the same five drivers are why a lot of the spending is wasteful. High agency and high information asymmetry produce confident wrong calls all the time. Buying a peptide regimen because a podcast guest recommended it is, in expected-value terms, not a good trade for most of the buyers making it.
How it works
The personal-spending stack has four moving parts and they run simultaneously.
The first is baseline diagnostics. Once a year, the buyer at the upper tier walks through a full-body MRI (Human Longevity, Prenuvo, or Ezra), a coronary CT angiogram run through an AI plaque-quantification engine like Cleerly, a DEXA scan for body composition and bone density, a VO₂-max test on a treadmill or bike, and a blood panel that runs to 100-plus markers. Add an epigenetic-age test — TruDiagnostic’s DunedinPACE is the consumer standard at about $349 — and a multi-cancer screening blood test like GRAIL’s Galleri at $949 if the buyer is over 50. The day costs $5,000–$15,000 depending on the clinic and what is included in the membership.
The second is the off-label pharmacy. Rapamycin, low-dose, weekly, was the signature longevity drug of the early 2020s; Peter Attia and rapamycin researcher Mikhail Blagosklonny remain proponents. Bryan Johnson himself dropped rapamycin in 2026 citing side effects — elevated glucose, infection susceptibility, slow wound healing. Metformin is the second drug in the canonical stack, popularized by David Sinclair; Sinclair has reportedly switched to berberine over gastrointestinal complaints. Low-dose GLP-1s — semaglutide, tirzepatide — moved into the longevity conversation post-2024 as metabolic-aging tools rather than weight-loss drugs; the compounded version that made them affordable for a year or two closed in 2025 when the FDA pulled them from the shortage list. Around those three sit a longer list — testosterone or HGH (controversial), NAD precursors, taurine, glycine, lithium orotate, urolithin A — that comprises most of the supplement spend.
The third is lifestyle infrastructure. A continuous glucose monitor (Levels, NutriSense, or the now-OTC sensors from Abbott and Dexcom) runs $150–$300 a month. An Oura or Whoop tracks sleep and heart-rate variability. Structured resistance training two or three times a week with a coach who understands longevity protocols runs $400–$1,500 a month. Cardio targeting Zone 2 and occasional VO₂-max intervals is part of the same line item.
The fourth is experimental — stem cell infusions abroad (Mexico, Panama, Antigua, the Bahamas, where the regulatory environment permits what the US does not), plasma exchange (Bryan Johnson’s televised multigenerational version of which is what most readers remember from Don’t Die), hyperbaric oxygen, cryotherapy, peptides like BPC-157 or thymosin alpha-1. The evidence base thins quickly moving down this list. The cost rises in roughly the inverse direction.
The institutional stack works on a different timescale entirely. Altos Labs is pursuing partial epigenetic reprogramming using Yamanaka factors — the four transcription factors that won Shinya Yamanaka the 2012 Nobel Prize for turning adult cells back into pluripotent stem cells. The bet is that partial reprogramming can rewind cellular age without erasing cell identity. Calico has worked on the same problem from a different angle for over a decade. Neither has a product on the market. Neither will help a founder who funds it today.
What it costs
The four personal-spending tiers, with USD ranges that are defensible rather than precise. All figures are 2026.
| Tier | Annual cost | Typical household | What you actually get |
|---|---|---|---|
| DIY (T1) | $1,500–$5,000 | $0–$5M net worth, or any income with high motivation | Supplement stack ($50–$200/month), one or two epigenetic-age tests/year ($349 TruDiagnostic), a smart ring or CGM, gym membership, occasional consult |
| Diagnostics + concierge (T2) | $5,000–$25,000 | $5M–$30M | Sollis Health Standard ($4,000) or Family ($10,000), MDVIP ($1,800–$4,500 depending on physician and location), Fountain Life CORE ($2,995), one full-body MRI/year ($1,500–$3,000), Galleri ($949 list, ~$799 self-pay), epigenetic clock |
| Full clinic stack (T3) | $25,000–$150,000 | $30M–$100M | Fountain Life APEX ($19,500–$21,500), Human Longevity 100+ Concierge ($19,000), or Peter Attia practice (well into six figures, referral only), plus dedicated physician + dietitian + trainer + quarterly imaging |
| Personal research budget (T4) | $250,000–$2M+ | $100M+ to $1B+ | Full-time medical team, custom-compounded interventions, weekly biomarker testing, frequent imaging, experimental protocols, occasional travel to specialist clinics |
The institutional spend sits in a separate column entirely:
- Altos Labs: $3 billion launch round in 2022 from Bezos, Milner, and ARCH Venture Partners.
- Calico: roughly $2.5 billion in combined Alphabet and AbbVie commitments since 2013.
- Hevolution Foundation: up to $1 billion a year pledged by the Saudi government; over $400 million committed to date globally.
- Ellison Medical Foundation: roughly $430 million committed cumulatively to aging research before closing the program to new grants in 2013.
- Sergey Young’s Longevity Vision Fund: $100 million targeting longevity startups, with the founder providing seed capital for the XPRIZE Healthspan.
- Breakthrough Prize (Milner): $3 million annual life-sciences prizes, with aging biology a recurring beneficiary.
The combined institutional bet on longevity since 2013 now sits north of $10 billion, which is roughly twice what the National Institute on Aging’s NIH allocation has been across the same period and is materially changing what gets researched.
Hidden costs and tradeoffs
The most underdiscussed cost in the upper tiers is overdiagnosis. Asymptomatic whole-body MRI screening finds incidental findings in 15–30% of scans, and the vast majority turn out to be benign. The follow-up — biopsies, repeat imaging, specialist consults, weeks of anxiety — is a real cost. Some of those findings save lives. Some lead to procedures the patient would have been better off never having. The American College of Radiology has been cautious about screening MRI in low-risk populations for exactly this reason. The clinics that sell the scan do not advertise this side of the ledger.
The second is off-label drug risk. Rapamycin’s side-effect profile — the exact reason Bryan Johnson dropped it in 2026 — is the kind of thing a buyer should weigh against an evidence base that is mostly mouse data. The compounded GLP-1 wave produced an underregulated supply chain; the FDA found products with no active ingredient, wrong doses, and labels naming pharmacies that did not exist. The personal-MD-as-pharmacist model collapses risk onto the buyer in a way that traditional medicine does not.
The third is lifestyle inflation around the protocol itself. A $25,000 diagnostic membership earns a checkup once a year. The dietitian, the trainer, the supplements, the time spent reading and adjusting and re-testing can run another $30,000–$60,000. The protocol becomes a part-time job, and the buyer who optimizes it most aggressively is also the buyer with the most expensive labor to redirect to it.
The fourth is the Bryan Johnson critique, which is the most honest critique in the field and which Johnson himself has consistently surfaced. By his own published Blueprint data, the gains he has measured — slower epigenetic aging, improved organ function, biological age markers below his chronological age — are heavily attributable to obsessive execution of the cheap parts of the protocol: sleep on schedule, never miss strength training, eat the same vegetable-heavy diet every day, never drink. An independent analysis by Empirical Health estimates that 80–90% of the protocol’s measurable benefit is reproducible at well under 1% of the cost — roughly $1,500–$2,000 a year of evidence-based basics. The remaining 10–20% — the plasma exchanges, the imported peptides, the once-a-month imaging cadence — is where most of the $2 million goes.
The fifth, for the institutional spenders, is the 80-year horizon problem. Aging biology operates on ten-to-twenty-year research timelines and longer regulatory ones. A 55-year-old founder who funds Altos in 2022 is not benefiting from Altos. He is funding the option that the science arrives in time for his grandchildren. The framing is generous; the personal payoff is not the point.
What people get wrong
Four corrections, tight.
The 1,000x spending gap is not a 1,000x healthspan gap. The single best-evidenced longevity interventions in 2026 are still: do not smoke, sleep seven or more hours a night, do resistance training twice a week, hold VO₂-max above the 50th percentile for your age, keep waist circumference reasonable, eat enough protein, and do not be lonely. None of these requires a clinic. None costs more than a gym membership. The wealthiest tier of buyers spends a thousand times more than a motivated DIY buyer and, on the available evidence, does not get a thousand times the result. The honest case for the high-tier spend is some of the marginal gain, plus better detection, plus the optionality bet on future breakthroughs — not a proportional return on dollars.
Concierge medicine is not longevity medicine. The two categories overlap in their customer base and in the language they use to sell themselves, but the products are different. Sollis, MDVIP, Private Medical, and the upper tier of urban concierge primary care buy access — same-day appointments, ER bypass, longer visits, after-hours phone numbers. They do not run anti-aging protocols. The post on concierge medicine covers that category in full. A buyer who wants both is buying two products, not one.
Most longevity supplements are still in evidence-gathering mode. NMN, NR, resveratrol, taurine, glycine, urolithin A — the mouse data is interesting, the human data is thin, and the human data we do have is mostly short-duration biomarker studies rather than long-duration outcome studies. Spending $500 a month on a stack does not buy proven years. It might buy proven years a decade from now. The honest framing for the buyer is that the supplement stack is a wager with an upside priced in years and a downside priced in dollars — and that the wager is reasonable at the dollar level it is being made at, but should not be confused with treatment.
The billionaire research funding is not selfish. This is the strongest defense of the institutional spend, and it is the one most often missed by readers who treat all longevity dollars as the same. Even if Calico and Altos never deliver a personal benefit to Bezos or Larry Page, the basic-science output spills over the way that any well-funded basic-research program does. Yamanaka factor partial reprogramming, senolytic therapeutics, in vivo gene therapies — the publishable knowledge from $10-plus billion of private aging-biology funding since 2013 has plausibly accelerated the broader field by a decade. The founders may not collect. The science will.
Bottom line
Bryan Johnson spends about $2 million a year on his longevity protocol. That is the answer to the question at the top. The number is not what is interesting about it. What is interesting is that his own published data, and an independent analysis of that data, suggests 80–90% of the measurable benefit comes from the cheap parts — sleep, training, diet, basic supplements — that any motivated adult can execute for about $1,500–$2,000 a year.
Below Johnson sit three smaller tiers. The full clinic stack ($25,000–$150,000) buys a defensible diagnostic suite, a dedicated team, and an early seat for whatever lands next. The diagnostics-and-concierge tier ($5,000–$25,000) buys the diagnostic suite without the team. The DIY tier ($1,500–$5,000) buys the basics, which is where most of the result is.
The defensible spend in 2026 is at the diagnostics layer — full-body MRI, coronary CT, multi-cancer blood screening, an epigenetic-age baseline — where money buys earlier detection and earlier detection genuinely improves outcomes. The speculative spend is everything past that, and it should be priced as the wager it is. The wealthy who get the most out of their longevity dollars are the ones who buy the diagnostics, execute the boring basics, and treat the peptide-and-stem-cell stack with the skepticism a thin evidence base earns.
The institutional billions are a separate category — a multi-decade option, paid for by people who probably will not be alive to collect, and on net good for everyone else.
Related reading:
- Concierge Medicine: Health Care for the Wealthy — the everyday-care category. Overlaps in marketing, different in product.
- Tech Wealth: How Founders and Investors Live Differently — longevity is the defining tech-wealth lifestyle category.
- Wealth Levels: Life at $1M, $10M, $100M, and $1B — the bracket shorthand used throughout this piece.
- [Family
